{"title":"[抗 FXII 疗法作为血栓性炎症靶点的临床开发]。","authors":"","doi":"10.1016/j.revmed.2024.03.012","DOIUrl":null,"url":null,"abstract":"<div><p>The history of anticoagulation has evolved considerably, from non-specific drugs to molecules that directly target specific coagulation factors, such as direct oral anticoagulants (DOACs). Since last decade, DOACs are widely used in clinical practice because of their ease to use with favorable pharmacological profile and not requiring monitoring. New therapeutics targeting the contact phase of coagulation are currently under development, and could make it possible to prevent thrombotic risk without altering hemostasis, thereby reducing the risk of bleeding. Factor XII, being at the crossroads between hemostasis and inflammation, appears to be an interesting target that could limit thrombo-inflammation without increasing bleeding risk. The aim of this article is to summarize the main information concerning FXII inhibitors and to review the results of various clinical trials available to date, focusing on applications beyond hemostasis, such as in the management of hereditary angioedema.</p></div>","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0248866324000924/pdfft?md5=2c489457ac4ab2bfd01549b39d675153&pid=1-s2.0-S0248866324000924-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Développement clinique des thérapeutiques anti-facteur XII ciblant la thrombo-inflammation\",\"authors\":\"\",\"doi\":\"10.1016/j.revmed.2024.03.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The history of anticoagulation has evolved considerably, from non-specific drugs to molecules that directly target specific coagulation factors, such as direct oral anticoagulants (DOACs). Since last decade, DOACs are widely used in clinical practice because of their ease to use with favorable pharmacological profile and not requiring monitoring. New therapeutics targeting the contact phase of coagulation are currently under development, and could make it possible to prevent thrombotic risk without altering hemostasis, thereby reducing the risk of bleeding. Factor XII, being at the crossroads between hemostasis and inflammation, appears to be an interesting target that could limit thrombo-inflammation without increasing bleeding risk. The aim of this article is to summarize the main information concerning FXII inhibitors and to review the results of various clinical trials available to date, focusing on applications beyond hemostasis, such as in the management of hereditary angioedema.</p></div>\",\"PeriodicalId\":54458,\"journal\":{\"name\":\"Revue De Medecine Interne\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0248866324000924/pdfft?md5=2c489457ac4ab2bfd01549b39d675153&pid=1-s2.0-S0248866324000924-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue De Medecine Interne\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0248866324000924\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue De Medecine Interne","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0248866324000924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
从非特异性药物到直接针对特异性凝血因子的分子,如直接口服抗凝剂(DOACs),抗凝剂的历史发生了巨大的演变。自过去十年以来,DOACs 因其使用方便、药理作用良好且无需监测而被广泛应用于临床实践。目前,针对凝血接触期的新疗法正在研发中,这些新疗法可以在不改变止血状态的情况下预防血栓风险,从而降低出血风险。因子 XII 处于止血和炎症的交叉点,似乎是一个有趣的靶点,可以在不增加出血风险的情况下限制血栓-炎症。本文旨在总结有关 FXII 抑制剂的主要信息,并回顾迄今为止各种临床试验的结果,重点关注止血以外的应用,如治疗遗传性血管性水肿。
Développement clinique des thérapeutiques anti-facteur XII ciblant la thrombo-inflammation
The history of anticoagulation has evolved considerably, from non-specific drugs to molecules that directly target specific coagulation factors, such as direct oral anticoagulants (DOACs). Since last decade, DOACs are widely used in clinical practice because of their ease to use with favorable pharmacological profile and not requiring monitoring. New therapeutics targeting the contact phase of coagulation are currently under development, and could make it possible to prevent thrombotic risk without altering hemostasis, thereby reducing the risk of bleeding. Factor XII, being at the crossroads between hemostasis and inflammation, appears to be an interesting target that could limit thrombo-inflammation without increasing bleeding risk. The aim of this article is to summarize the main information concerning FXII inhibitors and to review the results of various clinical trials available to date, focusing on applications beyond hemostasis, such as in the management of hereditary angioedema.
期刊介绍:
Official journal of the SNFMI, La revue de medecine interne is indexed in the most prestigious databases. It is the most efficient French language journal available for internal medicine specialists who want to expand their knowledge and skills beyond their own discipline. It is also the main French language international medium for French research works. The journal publishes each month editorials, original articles, review articles, short communications, etc. These articles address the fundamental and innumerable facets of internal medicine, spanning all medical specialties. Manuscripts may be submitted in French or in English.
La revue de medecine interne also includes additional issues publishing the proceedings of the two annual French meetings of internal medicine (June and December), as well as thematic issues.